FIELD: pharmaceutics; medicine.
SUBSTANCE: invention relates to the field of pharmaceutics and medicine, namely to a method for neo-adjuvant therapy in muscular invasive bladder cancer (hereinafter – MIBC) or non-muscular invasive bladder cancer (hereinafter – NMIBC) with a high risk of progression of bladder cancer in a patient, who has been prescribed cystectomy, wherein the specified therapy includes administration to the bladder of the specified patient of a composition containing complex hexyl 5-ALA ester (hereinafter – HAL) or its pharmaceutically acceptable salt, and irradiation with a blue light of the internal part of the specified bladder, while a time interval between the specified neo-adjuvant therapy and cystectomy is from 0 to 6 weeks.
EFFECT: provision of neo-adjuvant in MIBC or NMIBC with a high risk of progression of bladder cancer in a patient, who has been prescribed cystectomy, using a composition containing HAL or its pharmaceutically acceptable salt.
15 cl
| Title | Year | Author | Number |
|---|---|---|---|
| INTRAVESICAL THERAPY FOR BLADDER CANCER | 2016 |
|
RU2779543C2 |
| METHOD OF PHOTODYNAMIC THERAPY (PDT) OF BLADDER CANCER | 2016 |
|
RU2745194C2 |
| CHROMOGRANIN A AS MARKER OF BLADDER CANCER | 2017 |
|
RU2785737C2 |
| METHOD FOR TREATMENT OF CANCER OF LOWER PATHWAY UROTHELIUM | 2017 |
|
RU2764747C2 |
| USING 5-AMINOLEVULINIC ACID AND DERIVATIVES THEREOF IN SOLID FORM FOR PHOTODYNAMIC TREATMENT AND DIAGNOSTICS | 2008 |
|
RU2521228C2 |
| COMBINATION OF TASQUINIMOD OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND PD-1 AND/OR PD-L1 INHIBITOR FOR USE AS A MEDICINAL AGENT | 2016 |
|
RU2742373C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| COMBINED TREATMENT METHODS USING ALK INHIBITORS | 2015 |
|
RU2718914C2 |
| MULTI-SPECIFIC ANTIBODIES INTENDED FOR USE IN TREATMENT OF URINARY TRACT NEOPLASM | 2017 |
|
RU2766358C2 |
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER | 2018 |
|
RU2771759C2 |
